Advertisement

Breast Cancer Symposium - Enhancing Clinical Care Through Collaboration

2014 Meeting Program

2014 Breast Cancer Symposium Program Agenda

Jump to Day: Thursday | Friday | Saturday

  Thursday, September 4, 2014

7:00 AM —
6:00 PM

Exhibits Open

7:00 AM —
7:45AM

Complimentary Continental Breakfast

7:45 AM —
8:15 AM

Welcome and Framing Case Presentation of the Day

8:15 AM —
9:45 AM

General Session 1: Margins in Breast Conserving Surgery: Multidisciplinary Implementation of New Guidelines (ARS)
Chairs: Meena Moran, MD – Yale University
Monica Morrow, MD – Memorial Sloan Kettering Cancer Center

Overview of the SSO/ASTRO Consensus Guidelines on Margins in Breast Conserving Surgery 
Meena Moran, MD – Yale University
Monica Morrow, MD – Memorial Sloan Kettering Cancer Center

Pathology Assessment of the Partial Mastectomy Specimen
Stuart Schnitt, MD – Beth Israel Deaconess Medical Center and Harvard Medical School

 

The Role of Imaging in Margin Assessment
Carol Lee, MD – Memorial Sloan Kettering Cancer Center

Approaches to Breast Surgery Minimizing the Risk for Positive Margins
Benjamin Anderson, MD – Seattle Cancer Care Alliance

Radiation Oncologist’s View of Positive, Negative, or Close Margins: Is There a Difference?
Bruce Haffty, MD – Rutgers Cancer Institute of New Jersey

Systemic Chemotherapy Issues in the Era of Minimally Invasive Approaches to the Breast and Axilla
Harold Burstein, MD, PhD – Dana-Farber Cancer Institute

Panel Case Discussion

Q&A

9:45 AM —
10:15 AM

Break

10:15 AM —
11:45 AM

General Session 2: Genetic Risk Assessment and Prevention (ARS)
Chairs: Kristie Bobolis, MD – Capital Hematology Oncology Group
Gary Freedman, MD – Perelman School of Medicine, University of Pennsylvania 

Genetic Testing Panels
Susan Boolbol, MD - Beth Israel Medical Center, Continuum Cancer Centers of New York

Hereditary Risk Management
Banu Arun, MD – The University of Texas MD Anderson Cancer Center

Management of Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, and Lobular Carcinoma In Situ
Lynn Hartmann, MD – Mayo Clinic

Ductal Carcinoma In Situ Debate: Treatment versus Observation
Treatment: Henry Mark Kuerer, MD, PhD – The University of Texas MD Anderson Cancer Center

Observation: TBD

Q&A

11:45 AM —
1:30 PM

General Poster Session A
(With complimentary boxed lunch)

Biology in Local/Regional Management: Poster Boards A2 – A5, A8 – C15
General Screening: Poster Board A1
Health Policy: Poster Boards A6, C23 – D1
Management of Node-Positive Disease: Poster Boards C16 – C22

12:30 PM —
1:15 PM

General Session 3: Early Disease Tumor Board (ARS)

Submit your case to the early disease tumor board

1:30 PM —
3:00 PM

Oral Abstract Session A: Local/Regional Therapy, Survivorship, and Health Policy

Abstract 59: Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated partial-breast irradiation.
Presenting Author: Jessica Wobb

 Abstract 60: Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer.
Presenting Author: Catherine Parker

Abstract 61: Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC).
Presenting Author: Eleftherios P. Mamounas

Abstract 62: A NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction.
Presenting Author: Amanda Kathryn Silva

Abstract 104: Disparities in utilization of breast conserving therapy among breast cancer patients.
Presenting Author: Meeghan A. Lautner

Abstract 105: Long-term outcome results of the phase III promise-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.
Presenting Author: Matteo Lambertin

 Q&A

3:00 PM —
3:15 PM

Break

3:15 PM —
4:30 PM 

General Session 4: Risk-Adjusted Screening and Management
Chair: Anna Maria Storniolo, MD – Indiana University Simon Cancer Center

Does One Size Fit All? The Tailored-Screening Debate
Stephen Feig, MD – University of California, Irvine

IBIS-II Prevention Study: Chemotherapy Prevention and Risk Reduction
Jack M. Cuzick, PhD – Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine

Nonmedicinal Approach to Risk Modification
Ann Partridge, MD, MPH – Dana-Farber Cancer Institute

Abstract 1: Improving screening mammography return rates in overdue    women: A randomized study of signed reminder letters from family physicians. – 15 minutes Presenting Author: Elisa K. Chan

Q&A

4:30 PM —
4:45 PM 

Framing Case Summary of the Day

4:45 PM —

6:00 PM 

General Poster Session A and Networking Reception
(With complimentary wine and cheese)

Biology in Local/Regional Management: Poster Boards A2 – A5, A8 – C15
General Screening: Poster Board A1
Health Policy: Poster Boards A6, C23 – D1
Management of Node-Positive Disease: Poster Boards C16 – C22

5:00 PM —

6:00 PM 

Fellows, Residents, and Junior Faculty Networking Reception
(Ticketed session; limited to Fellows, Residents, and Junior Faculty)

Friday, September 5, 2014

7:00 AM —
6:00 PM

Exhibits Open

7:00 AM —
8:00 AM

Complimentary Continental Breakfast

6:55 AM —
7:55 AM

Meet the Professor Sessions
(Four concurrent ticketed sessions; breakfast provided)

Journal Review 101: Evaluating Scholarly Articles (Limited to Fellows, Residents, and Junior Faculty)
TBD

Management of the Primary Tumor in Stage IV Disease
Julia White, MD - The Ohio State University College of Medicine

Impact of Neoadjuvant Treatment on Local Therapy
David Brenin, MD
– University of Virginia

Management of the Axilla
Manjeet Chadha, MD - Beth Israel Medical Center

8:00 AM —
8:15 AM


Welcome and Framing Case Presentation of the Day

8:15 AM —
9:30 AM

General Session 5: New Directions in Neoadjuvant Therapy
Chair: Hope Rugo, MD, – UCSF Helen Diller Family Comprehensive Cancer Center

Neoadjuvant Therapy as a Mechanism for Drug Approval
Angela DeMichele, MD – Abramson Cancer Center of the University of Pensylvania

Understanding the Data and Its Application to the Clinic: When Do We Take Pathologic Complete Response Data to the Clinic to Change Therapy?
William Sikov, MD – Alpert Mecial School of Brown University

Immune Modulation as a Novel Strategy to Improve Host Response
Heather McArthur, MD – Memorial Sloan Kettering Cancer Center

Postneoadjuvant Therapy: What Do We Know and What Does the Future Hold?
Gunter Von Minckwitz, MD - German Breast Group

Q&A

9:30 AM —
9:45 AM

Break

9:45 AM —
10:20 AM

Gianni Bonadonna Breast Cancer Award

10:20 AM —
10:30 AM

Break

10:30 AM —
12:00 PM 

General Session 6: Survivorship and Health Policy
Chairs: Julie Gralow, MD – Seattle Cancer Care Alliance
Cliff Hudis, MD – Memorial Sloan Kettering Cancer Center

Psychosocial Issues in Breast Cancer Survivorship
Barbara Andersen, PhD - The Ohio State University Comprehensive Cancer Center

Lifestyle Modifications in Cancer Survivors
Pamela Goodwin, MD, MSc, FRCPC – Lunenfeld-Tanenbaum Research Institute

Debate: Post-treatment Surveillance—Intensive versus Nonintensive Monitoring
Pro (Intensive Surveillance): N. Lynn Henry, MD, PhD - University of Michigan Medical Center
Con (ASCO Choosing Wisely Campaign: Nonintensive): Gary Lyman, MD, MPH - Fred Hutchinson Cancer Research Center

Long-Term Health Outcomes
Sharon Giordano, MD, MPH - The University of Texas MD Anderson Cancer Center

Q&A

12:00 PM —
1:00 PM

General Poster Session B
(With complimentary boxed lunch)

Advanced Disease: Poster Boards D8 – D24
General Screening: Poster Boards A6 – B16
Genomics: Poster Boards B17 – C8
High Risk: Poster Boards A1 – A3, C9 – D7
HER2+: Poster Boards A4, D25 – E3
Triple-Negative: Poster Boards A5, E4 – E10

1:00 PM —
2:30 PM

Oral Abstract Session B: Systemic Therapy and Risk Assessment, Prevention, Early Detection, and Screening

Abstract 2: High incidence of germline BRCA mutation in patients with ER-low positive/PR negative/HER-2 neu negative tumors.
Presenting Author: Rachel A. Sanford

Abstract 3: A multivariate model to predict cancer upgrade from atypical ductal hyperplasia by core needle biopsy.
Presenting Author: Alvaro Pena

Abstract 4: Surgical outcome of lobular neoplasia diagnosed in core biopsy: Prospective study of 316 cases.
Presenting Author: Barbara Susnik

Abstract 134: Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Presenting Author: Erika J. Schneble

Abstract 135: Outcome of BRCA 1/2-Mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).
Presenting Author: Shalu Pahuja

Q&A

 

2:30 PM —
3:00 PM

Break

3:00 PM —
4:15 PM

General Session 7: Multidisciplinary Considerations in the Management of Patients Undergoing Breast Reconstruction
Chairs: Kelly Hunt, MD – The University of Texas MD Anderson Cancer Center

 
Breast Reconstruction in Patients Who Will Receive Postmastectomy Radiation Therapy
Amy Alderman, MD, MPH – Swan Center for Plastic Surgery
 
Radiation Oncology Treatment Planning and the Reconstructed Breast
Frank Vicini, MD - 21st Century Oncology
 
Mastectomy and Reconstruction Issues in Patients with Stage II and III Breast Cancer
TBD

Understanding the Impact of Radiation on Breast Cancer Outcomes 
Julia White, MD – The Ohio State University

Q&A

 

4:15 PM —
4:30 PM

Framing Case Summary of the Day

4:30 PM —
6:00 PM

General Poster Session B and Networking Reception
(With complimentary wine and cheese)

Advanced Disease: Poster Boards D8 – D24
General Screening: Poster Boards A6 – B16
Genomics: Poster Boards B17 – C8
High Risk: Poster Boards A1 – A3, C9 – D7
HER2+: Poster Boards A4, D25 – E3
Triple-Negative: Poster Boards A5, E4 – E10

5:00 PM —

6:00 PM

Meet the Professor Sessions
(Four concurrent ticketed sessions)

The Future of Oncology and the Affordable Care Act
Clifford Hudis, MD - Memorial Sloan Kettering Cancer Center
 
Applying New Adjuvant Data to the Clinic
Sandra Swain, MD, FACP
– MedStar Washington Hospital Center
and
Joseph Sparano, MD
– Montefiore Medical Center
 
Treating HER2-Positive Disease in 2014
Sara Hurvitz, MD
– UCLA/Jonsson Comprehensive Cancer Center
 
Controversies and New Technologies in Breast Imaging
TBD

 

Saturday, September 6, 2014

7:00 AM —
8:00 AM

Complimentary Continental Breakfast
 

8:00 AM —
8:15 AM

Welcome and Framing Case Presentation of the Day

8:15 AM —
9:45 AM

General Session 8: Evolving Standards in the Treatment of Breast Cancer (ARS)
Chair: William Gradishar, MD – Northwestern University Feinberg School of Medicine

Extended Adjuvant Hormone Therapy: Aromatase Inhibitors and Tamoxifen
Ruth O’Regan, MD – Georgia Cancer Center for Excellence at Grady Memorial Hospital

Evolving Standards in the Treatment of Early-Stage Breast Cancer
Charles Geyer, MD, FACP - University of Texas Southwestern Medical Center

Evolving Standards of Early Stage Her 2 Positive Breast Cancer
Sunil Verma, MD, MSEd, FRCP(C) – Sunnybrook Odette Cancer Centre

Debate on Bisphosphonates for the Treatment of Early-Stage Breast Cancer
Pro - Julie Gralow, MD – Seattle Cancer Care Alliance
Con - Anthony Elias, MD - University of Colorado School of Medicine

Q&A

9:45 AM —
10:00 AM


Break

10:00 AM —
10:45 AM

General Session 9: Metastatic Disease Tumor Board (ARS)

Submit your case to the metastatic disease tumor board 

10:45 aM —
11:00 AM

Break

11:00 AM —
12:15 PM

General Session 10: Genomics and Reversing Hormone Resistance
Chair: Stephen Chia, MD – British Columbia Cancer Agency

Understanding Mechanisms of Resistance to Hormone Therapy 

Suzanne Fuqua, PhD - Baylor College of Medicine

Emerging Data on Improving Response to Hormone Therapy: The Role of Novel Targeted Agents
Hope Rugo, MD – UCSF Helen Diller Family Comprehensive Cancer Center

Next-Generation Sequencing for Determining Treatment in Breast Cancer: Ready for Prime Time? 
Lajos Pusztai, MD, PhD – Yale School of Medicine

Q&A

12:15 PM

Adjourn